Literature DB >> 30841767

A Meta-Analysis of the Outcomes of Split-Thickness Skin Graft on Diabetic Leg and Foot Ulcers.

Kaissar Yammine1, Chahine Assi1.   

Abstract

Diabetic lower limb ulcers are a serious complication to diabetes that could lead to amputation and death. Split-thickness skin graft (STSG) has been proposed by some authors to treat noninfected diabetic wounds, mainly those found in the leg and on the dorsum of the foot. No quantitative evidence synthesis over this technique has been reported in the literature. The study is a meta-analysis on the effectiveness of STSG in treating diabetic leg and foot ulcers. Electronic databases were searched from inception. No limitation was imposed on study design. Eleven studies comprising 757 patients with 759 foot/leg ulcers were included. After a mean period of 2 years, 85.5% (95% confidence interval [CI] = 0.766-0.925) of ulcers were healed over a mean time of 5.35 ± 2.25 weeks, with a recurrence rate of 4.2% (95% CI = 0.009-0.096), an infection rate of 4.4% (95% CI = 0.013-0.092), and a regrafting rate of 12.1% (95% CI = 0.053-0.212). Infection was the only reported donor site morbidity with a frequency of 1.74% (95% CI = 0.001-0.048). These weighted values are found to be noticeably superior to those reported in the literature following standard conventional care. The results of the review make STSG the ideal method to treat noninfected recurrent or recalcitrant ulcers of the leg and dorsal foot. Furthermore, the authors argue that STSG should be used more frequently in the management of such wounds. The findings should encourage future prospective investigations.

Entities:  

Keywords:  diabetic foot ulcer; leg ulcer; split-thickness skin graft

Mesh:

Year:  2019        PMID: 30841767     DOI: 10.1177/1534734619832123

Source DB:  PubMed          Journal:  Int J Low Extrem Wounds        ISSN: 1534-7346            Impact factor:   2.057


  6 in total

Review 1.  A Systematic Review on the Outcomes of the Fillet Flap in Treating Diabetic and Ischemic Forefoot Ulcers.

Authors:  Kaissar Yammine; Chahine Assi
Journal:  Plast Surg (Oakv)       Date:  2020-07-01       Impact factor: 0.558

2.  ENERGI-F703 gel, as a new topical treatment for diabetic foot and leg ulcers: A multicenter, randomized, double-blind, phase II trial.

Authors:  Jui-Yung Yang; Cha-Chun Chen; Shun-Cheng Chang; Jiun-Ting Yeh; Hui-Fu Huang; Hwang-Chi Lin; Shang-Hsi Lin; Yu-Hsien Lin; Lin-Gwei Wei; Tom J Liu; Shih-Yuan Hung; Hui-Mei Yang; Hui-Hsiu Chang; Chih-Hsin Wang; Yuan-Sheng Tzeng; Chieh-Huei Huang; Chang-Yi Chou; Ying-Sheng Lin; Shih-Yi Yang; Han-Min Chen; Jiun-Tsai Lin; Yi-Fang Cheng; Guang-Huar Young; Chun-Fang Huang; Ya-Chun Kuo; Niann-Tzyy Dai
Journal:  EClinicalMedicine       Date:  2022-07-10

Review 3.  Innovative Cell and Platelet Rich Plasma Therapies for Diabetic Foot Ulcer Treatment: The Allogeneic Approach.

Authors:  Maddalena Mastrogiacomo; Marta Nardini; Maria Chiara Collina; Cristiana Di Campli; Gilberto Filaci; Ranieri Cancedda; Teresa Odorisio
Journal:  Front Bioeng Biotechnol       Date:  2022-05-02

4.  Limb salvage procedure in immunocompromised patients with therapy-resistant leg ulcers-The value of ultra-radical debridement and instillation negative-pressure wound therapy.

Authors:  Alexander Geierlehner; Raymund E Horch; Wibke Müller-Seubert; Andreas Arkudas; Ingo Ludolph
Journal:  Int Wound J       Date:  2020-06-22       Impact factor: 3.315

5.  Chronic wounds: Treatment consensus.

Authors:  Elof Eriksson; Paul Y Liu; Gregory S Schultz; Manuela M Martins-Green; Rica Tanaka; Dot Weir; Lisa J Gould; David G Armstrong; Gary W Gibbons; Randy Wolcott; Oluyinka O Olutoye; Robert S Kirsner; Geoffrey C Gurtner
Journal:  Wound Repair Regen       Date:  2022-02-07       Impact factor: 3.401

6.  Wound location is independently associated with adverse outcomes following first-time revascularization for tissue loss.

Authors:  Jeremy D Darling; Thomas F X O'Donnell; Giap H Vu; Anthony V Norman; Emily St John; Lars Stangenberg; Mark C Wyers; Allen D Hamdan; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2020-08-29       Impact factor: 4.268

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.